drugset / Trial / NCT01765855

An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects

NCT01765855

Phase 1 Completed 5 enrolled Portola Pharmaceuticals
NaSingle-groupOpen-labelBasic science

Summary

This is a open label, single center, single oral dose, study of PRT054021, in healthy subjects.

Timeline

Start
2007-09
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Betrixaban Small molecule Oral

Indications

No indication recorded.